|Application ||IHC-F, E, Func|
|Immunogen||Human RSV isolate.|
|Shelf Life||18 months from the date of despatch.|
|Target/Specificity||Goat anti-respiratory syncitial virus polyclonal antibody recognizes respiratory syncytial virus (RSV) a negative-sense, single-stranded RNA virus and member of the Paramyxoviridae family. RSV causes respiratory tract infections in patients of all ages, but particularly affects infants and the immunosuppressed.RSV encodes three envelope glycoproteins, a small hydrophobic (SH) protein of unknown function, a glycoprotein (G) known as the attachment protein, and a fusion (F) protein. The F protein directs fusion of viral and cellular membranes, resulting in viral penetration, and can lead to the formation of syncytia. The F protein is thought to be the principal antigen responsible for inducing an immune response.Goat anti-respiratory syncitial virus does not react with Parainfluenza 1-3, Influenza A and B, Adenovirus or uninfected HEp-2 or WI-38 cells. Goat anti-respiratory syncitial virus polyclonal antibody is neutralizing and reacts well with bovine isolates.|
|Preservative & Stabilisers||0.09% Sodium Azide (NaN3)|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-Respiratory Syncytial Virus Antibody (Biotin) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Culley, F.J. et al. (2006) Role of CCL5 (RANTES) in viral lung disease. J Virol. 80: 8151-7. 2. Numata, M. et al. (2010) Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.Proc Natl Acad Sci U S A. 107: 320-5. 3. Roux, X. et al. (2008) Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus.PLoS One. 3: e1766. 4. Olszewska, W. et al. (2011) Antiviral and lung protective activity of a novel RSV fusion inhibitor in a mouse model.Eur Respir J. 38: 401-8. 5. Fonceca AM et al. (2012) Primary airway epithelial cultures from children are highly permissive to respiratory syncytial virus infection.Thorax. 67 (1): 42-8. 6. Ryzhakov, G. et al. (2011) IL-17 Boosts Proinflammatory Outcome of Antiviral Response in Human Cells.J Immunol. 187: 5357-62. 7. Fricke J et al. (2013) p38 and OGT sequestration into viral inclusion bodies in cells infected with human respiratory syncytial virus suppresses MK2 activities and stress granule assembly.J Virol. 87 (3): 1333-47. 8. Kipper, S. et al. (2015) New host factors important for respiratory syncytial virus (RSV) replication revealed by a novel microfluidics screen for interactors of matrix (M) protein.Mol Cell Proteomics. 14 (3): 532-43. 9. Russell, R.F. et al. (2015) Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1β Responses.J Virol. 89 (17): 8974-81. 10. Currie S. M. et al. (2016) Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro In Vivo in Mice and Humans.The Journal of Immunology. Feb 12 [Epub ahead of print]
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.